Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$6.54 USD

6.54
223,956

+0.33 (5.31%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $6.54 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 44.44% and 2.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.

Zacks Equity Research

Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales

by Zacks Equity Research

Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.

Zacks Equity Research

Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.

Zacks Equity Research

Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Inogen (INGN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 18.18% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Inogen (INGN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Strength Seen in Inogen (INGN): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Inogen (INGN) Q4 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen (INGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen (INGN) Announces Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.

Zacks Equity Research

Why Is Shockwave Medical (SWAV) Down 8.3% Since Last Earnings Report?

by Zacks Equity Research

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

Zacks Equity Research

Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 56.10% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Inogen (INGN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Zacks Equity Research

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.